Vimpat ® is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. The Applicant is seeking reimbursement for an extension to the product license to cover children (≥4 years of age) and adolescents (≤ 15 years of age).
|NCPE Assessment Process||Complete|
|Rapid review commissioned||11/09/2017|
|Rapid review completed||31/10/2017|
|Rapid Review outcome||A full pharmacoeconomic evaluation is recommended at the submitted price.